.png)
VUUAI ACQUIRES NOTE.AI TO ACCELERATE COMPLIANT CONTENT AUTOMATION IN PHARMA AND MEDTECH
January 9, 2026
VuuAI, an integrated, GenAI-driven, compliant content automation provider, has announced the acquisition of Note.AI, which provides AI-powered solutions for the life sciences industry. The acquisition includes the integration of the Note.MLR platform, the AI-powered MLR review tool designed, developed and refined by industry experts, which accelerates VuuAI’s plans to deliver compliant, on-brand and effective content for pharma and medtech companies.
Note.AI was founded in 2025 by Matthew Holman, who has 15 years’ experience in the content and MLR space, with the mission to leverage artificial intelligence to improve efficiencies, accuracy and processes through bespoke solutions and SaaS product development. Prior to Note.AI, Holman worked in several healthcare communications agencies and was a Director at PharmaReview, the largest outsourced provider of MLR services, which was acquired by IQVIA. The Note.MLR platform builds on this prior expertise to streamline medical, legal, and regulatory reviews in pharma/biotech, improving speed, quality, and compliance.
VuuAI’s approach goes beyond accelerating MLR to allow the rapid validation of compliance and pharma brand integrity, plus optimization, transformation and creation of brand and disease area content. The platform is backed by an industry team with significant experience spanning content, technology, medical and commercial operations, and enterprise-level workflow transformation. In the future, users of VuuAI are expected to be able to generate dynamic, personalized and approved marketing and medical content instantaneously, in any format, for delivery via any channel.
VuuAI is engaged with several leading pharmaceutical companies to implement its solutions and collaborate on future development. Matthew Holman joins the VuuAI team as SVP Product Strategy where he will refine specific industry use cases and lead the prioritization of product features.
The acquisition comes shortly after VuuAI announced a strategic partnership with leading global healthcare communications agency, Amiculum, to deploy VuuAI’s products.
“VuuAI is delighted to have Matthew Holman join the team at a time where we’re seeing considerable interest in our technology, with his expertise and existing platforms accelerating our plans to help pharma and medtech clients deliver compliant, on-brand and effective content, in a personalized way and at scale”
DR PAUL TUNNAH, VUUAI CEO AND CO-FOUNDER
“It’s exciting to join VuuAI and be part of a highly experienced team with expertise spanning content, MLR, technology and enterprise scale workflow transformation. Together, we share an aligned vision for delivering more impactful commercial engagement through unlocking the power of content”
MATTHEW HOLMAN, NOTE.AI FOUNDING DIRECTOR
MORE ABOUT VUUAI
VuuAI transforms commercial and medical engagement using AI-powered automation to empower pharma and medtech teams to efficiently produce compliant, on-brand, and effective content, thereby accelerating the adoption of medical innovation.
​
The VuuAI team has unparalleled life sciences experience spanning content, technology, workflow optimization and enterprise-level transformation.
​
Investors and pharma / medtech customers can find out more information on VuuAI at the website: (https://www.vuu.ai/) or by emailing hello@vuu.ai
MORE ABOUT NOTE.AI
Note.AI provides AI-powered solutions for the life science industry, leveraging artificial intelligence to improve efficiencies, accuracy and processes through bespoke solutions and SaaS product development. Its portfolio includes Note.MLR, the AI-powered MLR review tool designed, developed and refined by industry experts that provides streamlined medical, legal, and regulatory reviews in pharma/biotech, improving speed, accuracy, and compliance.
For queries please contact VuuAI on the details above.